Novo Nordisk launches Wegovy in India for weight management, cardiovascular risk reduction

One-weekly injectable semaglutide, Wegovy is the first and only weight management medication in India indicated for both long-term chronic weight management and reduction in risk of major adverse cardiovascular events in people living with the condition, said the company in a statement.

It is being made available in five dosing strengths with an easy-to-use pen device which does away the use of syringes; therefore, can be self-administered at home.

India has the third highest number of people living with overweight and obesity. Alarmingly, obesity is associated with over 200 diseases, including cardiovascular diseases, certain types of cancer, and type 2 diabetes.